head and neck squamous cell carcinoma

head and neck squamous cell carcinoma
Name	Head and neck squamous cell carcinoma
Synonyms	HNSCC
Field	Oncology, Otolaryngology
Risks	Tobacco smoking, HPV, alcohol
Diagnosis	Biopsy, Endoscopy
Treatment	Surgery, Radiation therapy, Chemotherapy, Immunotherapy

head and neck squamous cell carcinoma is a major category of malignancies arising from the mucosal epithelium of the oral cavity, pharynx, and larynx. It represents the sixth most common cancer globally, with significant variations in incidence and etiology across different geographic regions. The disease is characterized by its strong association with specific lifestyle exposures and viral infections, leading to distinct molecular and clinical subtypes. Management requires a multidisciplinary approach involving specialists from Otolaryngology, Radiation oncology, and Medical oncology.

Epidemiology

The global incidence of this malignancy shows marked geographic disparity, with high rates reported in regions such as Melanesia, South-Central Asia, and Eastern Europe. In the United States, it accounts for approximately 4% of all cancers, with an estimated 66,000 new cases diagnosed annually according to the American Cancer Society. Historically, the disease has been more prevalent in men, particularly those over the age of 50, though changing risk factor profiles are altering this demographic. The World Health Organization notes a rising incidence of oropharyngeal cancers linked to HPV in many developed nations, including the United Kingdom and Scandinavia.

Risk factors

The primary established risk factors are Tobacco smoking and the use of smokeless tobacco products like Betel quid, which is endemic in parts of Southeast Asia and the Indian subcontinent. Heavy consumption of alcoholic beverages acts synergistically with tobacco to dramatically increase risk. Infection with oncogenic strains of the Human papillomavirus, particularly HPV16, is a dominant cause of oropharyngeal carcinomas, a shift documented by research from the National Cancer Institute and Johns Hopkins Hospital. Additional factors include poor oral hygiene, occupational exposures such as to Asbestos or Wood dust, and genetic syndromes like Fanconi anemia.

Pathophysiology

Carcinogenesis involves the accumulation of genetic and epigenetic alterations in squamous epithelial cells. In tobacco and alcohol-related cases, there is frequent mutation of the TP53 tumor suppressor gene and activation of pathways like the EGFR. HPV-positive tumors, often originating in the tonsillar crypts, are driven by the viral oncoproteins E6 and E7, which inactivate P53 and pRb, respectively. These molecular differences, studied at institutions like the MD Anderson Cancer Center, result in two biologically distinct entities with different clinical behaviors and responses to treatment.

Diagnosis

Diagnosis begins with a thorough clinical examination by an Otolaryngologist, often involving Flexible laryngoscopy or Panendoscopy. Definitive diagnosis requires a Biopsy of the suspicious lesion for histopathological analysis. Imaging studies are crucial for evaluating the extent of disease; CT and MRI of the head and neck are standard, while PET-CT is increasingly used for staging. For HPV-associated oropharyngeal cancer, testing for P16 overexpression or the presence of HPV DNA via PCR is now routine.

Staging

Staging follows the AJCC TNM staging system, which assesses the size and extent of the primary tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastases (M). A major update in the 8th edition, developed in collaboration with the UICC, created separate staging protocols for HPV-positive oropharyngeal cancers due to their superior prognosis. Accurate staging, which may involve examination under anesthesia at a center like the Mayo Clinic, is critical for determining prognosis and selecting appropriate therapy.

Treatment

Treatment is highly dependent on the tumor site, stage, and HPV status. Early-stage disease is often treated with single-modality therapy, such as Transoral robotic surgery or definitive Radiation therapy. Locally advanced disease typically requires multimodality treatment, combining Surgery (e.g., Laryngectomy or Neck dissection) with adjuvant Radiotherapy and Chemotherapy agents like Cisplatin. For recurrent or metastatic disease, systemic therapies including the EGFR inhibitor Cetuximab and Immunotherapy agents like Pembrolizumab and Nivolumab, approved by the FDA, are standard.

Prognosis

Prognosis varies widely based on stage, subsite, and etiology. The 5-year survival rate for early-stage disease can exceed 80-90%, but drops significantly for advanced stages with nodal involvement. HPV-positive oropharyngeal carcinomas have a markedly better prognosis compared to HPV-negative tumors, a finding confirmed by studies from the RTOG. Factors associated with poor outcomes include positive surgical margins, Extranodal extension of tumor in lymph nodes, and the presence of distant metastases to sites like the lungs or liver. Category:Head and neck cancer